Higuchi John W. purchased $27K of LPCN

Higuchi John W. purchased 12,561 shares of Lipocine Inc. (LPCN) at $2.16 on 2026-09-28.

Original reporting
SEC EDGAR · Higuchi John W.
Published Oct 1, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LPCN
Bullish
high confidence
Mentioned
$LPCN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LPCNBullishLow
01

Why it matters

Adds new data on insider ownership; limited market impact due to small size.

02

Market read

Minor insider purchase; unlikely to move the stock significantly.

03

What to watch

Insider may be buying for personal reasons unrelated to company outlook.

Relevance 4/10Novelty 5/10Timing: post-market today

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$LPCNBullishHigh confidence
Context

Director John W. Higuchi purchased 12,561 shares at $2.16, raising his stake to 216,358 shares.

Expected impact

potential slight upside as insider buying signals confidence

Evidence & confidence

The transaction is a primary Form 4 filing and adds new insider ownership, but the amount is modest.

Market effects

none

none

low

Counterpoint

The purchase is too small to affect price materially.

Key entities

  • Lipocine Inc.

    Biopharma company listed on NASDAQ.

  • John W. Higuchi

    Director of Lipocine Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LPCNLowAI 8/10

Lipocine Doses First Participant in Phase 3 BLOOM Study of LPCN 1154

Lipocine has dosed the first participant in its Phase 3 BLOOM study of LPCN 1154, an investigational 48-hour oral treatment for postpartum depression. The placebo-controlled study aims to enroll 120 participants, with topline results expected in the second half of 2027. The study incorporates FDA feedback and prior-trial learnings. LPCN 1154 previously failed to meet its primary endpoint in a Phase 3 trial.

$LPCNMed

Lipocine Announces Financial Results for the Third Quarter of 2026

Lipocine Inc. (LPCN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lipocine Announces Financial Results for the Third Quarter of 2026 SALT LAKE CITY, November 5, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the thi

$LPCNMedAI 8/10

A postpartum depression study from Lipocine is expected to enroll about 120 people.

Lipocine initiated a Phase 3 study for postpartum depression treatment BRLIZIO™, expecting to enroll 120 participants. The study aims to support a potential NDA submission. The company also reported financial results for Q3 and the first nine months of 2026, showing net losses and revenue. Lipocine is exploring partnerships for BRLIZIO™ and other programs, including LPCN 2201 for MDD and LPCN 2203 for essential tremor.